dr. camidge on met as a target in lung cancer
Published 9 years ago • 191 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
1:36
met as a clinical target in lung cancer
-
1:44
met as a secondary driver in lung cancer
-
1:09
dr. camidge on crizotinib as a ros1 inhibitor in nsclc
-
1:55
dr. d. ross camidge on targeted therapies in adjuvant non-small cell lung cancer
-
1:58
dr. camidge on mechanisms of resistance to tkis in nsclc
-
1:00
dr. camidge on phase i study with azd9291 in nsclc
-
1:29
dr. camidge on the unmet needs for lung cancer
-
1:00
dr. camidge discusses unmet needs in alk lung cancer
-
2:29
dr. ross camidge discusses crizotinib in ros1 rearranged nsclc
-
1:51
dr. camidge on biomarker combinations in nsclc
-
1:35
d. ross camidge discusses the development of a new lung cancer drug
-
1:37
dr. camidge on the alex trial in patients with alk nsclc
-
1:52
dr. camidge on optimal therapy in egfr nsclc
-
1:56
using emibetuzumab directed towards met for the treatment of lung cancer
-
1:28
dr. camidge on ap26113 in patients with advanced malignancies
-
1:34
dr. camidge on the alta study of brigatinib in nsclc
-
8:46
an update from asco 2018 on targeted therapies in lung cancer | ross camidge
-
9:36
dr. d ross camidge on teliso-v monotherapy in patients with previously treated c-met advanced nsclc
-
1:19
dr. ross camidge discusses resequencing lung cancer